Merck Adds Johns Hopkins Dean, Former Accenture CFO to Board

Merck & Co. added two members to its board, tapping academia and the consulting industry to bolster its corporate oversight.

Paul Rothman, dean of the medical faculty and vice president for medicine of Johns Hopkins University, and Pamela Craig, the former chief financial officer of Accenture Plc, will join Sept. 1, Merck said in a statement. The additions will expand Merck’s board to 14 members.

Chief Executive Officer Ken Frazier is pushing Merck further into the development of treatments for hard-to-fight diseases including cancer and Alzheimer’s, selling off a consumer business to Bayer AG for $14.2 billion last year.

The company raised its profit forecast for the year Tuesday after reporting second-quarter earnings that beat analysts’ estimates.

Before it's here, it's on the Bloomberg Terminal.